Schering Corporation

Merck Sharp + Dohme Corp.

Other

Brian J Lavey

Joseph A Kozlowski

Neng-Yang Shih

Ling Tong

Bandarpalle B Shankar

Guowei Zhou

Wensheng Yu

Michael K C Wong

De-Yi Yang

Dansu Li

Lei Chen

Razia Rizvi

Seong Heon Kim

Kristin E Rosner

M Arshad Siddiqui

Janeta Popovici-Muller

Vinay M Girijavallabhan

Chaoyang Dai

Zhuyan Guo

Peter Orth

Vincent Stewart Madison

Robert Feltz

Zhaoning Zhu

Brian Alexander McKittrick

Judson E Richard

Aneta Maria Kosinski

Luke Fire

Ronald L Wolin

Robert Mazzola

James M Spitler

Aneta M Micula

Michael K Wong

Lisa Sinning

Pauline C Ting

Deen Tulshian

Umar Faruk Mansoor

Richard J Friary

Liping Yang

Youheng Shu

W Michael Seganish

William T McElroy

Stephanie Brumfield

Seong-Heon Kim

William J Greenlee

Andrew William Stamford

Craig Alan Coburn

Michael D Altman

Michael P Dwyer

Stuart B Rosenblum

Michael W Miller

Jongwon Lim

Xing Dai

Gerald Wayne Shipps, Jr

Joey Lee Methot

Sunil Paliwal

Duane E DeMong

Robert D Mazzola, Jr

Tin-Yau Chan

Gregory A Reichard

Craig R Gibeau

John W Lampe

Lianyun Zhao

Ginny Dai Ho

David Benjamin Belanger

Henry A Vaccaro

Julius J Matasi

Liang Zhu

Nicholas I Carruthers

R Jason Herr

Shing-Chun C Wong

Cheryl A Alaimo

Larry Yet

Jinhai Yang

James P Harding, Iii

Michael Kc Wong

Kristen E Rosner

Aneta Maria Kosinzki

Shankar B Bandarpalle

Duane Eugene Demong

Razia K Rizvi

James P Iii Harding

Deen B Tulshian

William T Mcelroy

Stephanie Nicole Brumfield

John William Lampe

Michael KC Wong

Aneta S Micula

Robert Schering-Plough Corporation Feltz

The present invention relates to compounds which modulate interleukin-1 (IL-1) receptor-associated kinase 4 (IRAK4) and are useful in the prevention or treatment of inflammatory, cell proliferative and immune-related conditions and diseases. Specifically, provided herein are inhibitors of IRAK4 of Formula I and pharmaceutical compositions comprising such inhibitors, as well as methods therewith for treating IRAK4-mediated or -associated conditions or diseases.

Inhibitors of IRAK4 activity

The present invention relates to novel Fused Tetracycle Derivatives of Formula (I): and pharmaceutically acceptable salts thereof, wherein A, A', B, G, R, U, V, W, W&#x2032;, X, X&#x2032;, Y and Y&#x2032; are as defined herein. The present invention also relates to compositions comprising at least one Fused Tetracycle Derivative, and methods of using the Fused Tetracycle Derivatives for treating or preventing HCV infection in a patient. 

Fused tetracycle derivatives and methods of use thereof for the treatment of viral diseases

This invention relates to aminopyrimidinone compounds of Formula (I) that are inhibitors of Interleukin receptor-associated kinases, in particular IRAK-4, and are useful in the treatment or prevention of inflammatory diseases, including rheumatoid arthritis and inflammatory bowel disease.

Aminopyrimidinones as interleukin receptor-associated kinase inhibitors

This invention relates to compounds of the Formula (I) as described herein, or a pharmaceutically acceptable salt, solvate or ester thereof, which can be useful for the treatment of diseases or conditions mediated by MMPs, ADAMs, TACE, aggrecanase, TNF- or combinations thereof. 

Compounds for the treatment of inflammatory disorders

This invention relates to compounds of the Formula (I): (Chemical formula should be inserted here as it appears on abstract in paper form) (I) or a pharmaceutically acceptable salt thereof, which can be useful for the treatment of diseases or conditions mediated by MMPs, ADAMs, TACE, aggrecanase, TNF- or combinations thereof. 

This invention relates to compounds of the Formula (I): (Chemical formula should be inserted here as it appears on abstract in paper form) (I) or a pharmaceutically acceptable salt, solvate or isomer thereof, which can be useful for the treatment of diseases or conditions mediated by MMPs, ADAMs, TACE, aggrecanase, TNF&#x2014;or combinations thereof. 

This invention relates to compounds of the Formula (I)-(IX):, as defined herein, or a pharmaceutically acceptable salt, solvate or ester thereof, which can be useful for the treatment of diseases or conditions mediated by MMPs, ADAMs, TACE, aggrecanase, TNF-&#x3b1; combinations thereof. 

Compounds for the treatment of inflammatory diseases

The present invention relates to compounds of the general formula: (I) wherein ring A, ring B, R, R, Z, L, and Lare selected independently of each other and are as defined herein, to compositions comprising the compounds, and to methods of using the compounds as glucagon receptor antagonists and for the treatment or prevention of type 2 diabetes and conditions related thereto. 

Spiro-imidazolone derivatives as glucagon receptor antagonists

This invention relates to compounds of the Formula (I): 

There are disclosed compounds of the formula a prodrug thereof, or a pharmaceutically acceptable salt, solvate or stereoisomer of the compound or of said prodrug; which exhibit anti-inflammatory and immunodulatory activity. Also disclosed are pharmaceutical compositions containing said compounds and methods of using the compounds for the treatment of various diseases and conditions.

Cannabinoid receptor ligands

Growing community of inventors

Chatham, NJ, United States of America

Brian J Lavey